NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

TSX · Biotechnology · CAD

Microbix Biosystems Inc. (MBX.TO) Stock Analysis

Microbix Biosystems Inc. (MBX.TO) is a Biotechnology stock listed on TSX and quoted in Canadian Dollar.

Last Updated: October 21, 2026

MBX.TO

CA$0.32

CA$0.00 (0.00%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare MBX.TO with… →

MBX.TO Key Statistics

As of Oct 21, 2026
Trading
Open
CA$0.32
Previous Close
CA$0.32
Day's Range
0.32–0.32
52-Week Range
0.21–0.33
Volume
69.11K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.54
Valuation
Market Cap
CA$43.83M
P/E Ratio
unprofitable
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
16.00
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
2.85
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.04
Financials (FY)
Revenue (FY)
CA$18.59M−26.81%
Net Income (FY)
−CA$2.25M−163.80%
Profit marginThe share of revenue left as profit after all costs and taxes.
−31.72%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
136.97M
1-Year Return
+28.00%
Dividend and dates
Avg Volume
24.94K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, MBX.TO closed at CA$0.32, +28.00% over 1 year.

Microbix Biosystems Inc. (MBX.TO) has a market capitalization of CA$43.83M.

In fiscal 2025, MBX.TO reported revenue of CA$18.59M.

MBX.TO Stock Return by Calendar Year

Microbix Biosystems Inc. (MBX.TO) 10-year return: what CA$10,000 became

1 year
CA$10,000 CA$12,800
+28.00%
5 years
CA$10,000 CA$4,507
−54.93%
10 years
CA$10,000 CA$12,800
+28.00%

If you had invested CA$10,000 in Microbix Biosystems Inc. (MBX.TO) 10 years ago, at the close on October 21, 2016, it would have been worth CA$12,800 at the close on October 21, 2026: +28.00% in total, +2.50% a year. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+39.13%
2025−43.90%
2024+5.13%
2023−4.88%
2022−50.60%
2021+93.02%
2020+72.00%
2019+4.17%
2018−22.58%
2017+19.23%
2016 (partial year)−3.70%

As of October 21, 2026.

MBX.TO Revenue and Earnings by Fiscal Year

FY ends September
Fiscal yearRevenueNet incomeNet margin
2025CA$18.59M−CA$2.25M−12.1%
2024CA$25.39MCA$3.52M13.9%
2023CA$16.51M−CA$39.48K−0.2%
2022CA$19.08MCA$1.79M9.4%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025CA$18.59MCA$9.85M−CA$1.58M−CA$2.25M−12.1%
2024CA$25.39MCA$15.39MCA$3.90MCA$3.52M13.9%
2023CA$16.51MCA$7.48M−CA$2.74M−CA$39.48K−0.2%
2022CA$19.08MCA$11.12MCA$2.61MCA$1.79M9.4%

Annual figures as reported, in the company's reporting currency. As of September 30, 2025.

MBX.TO Valuation vs Biotechnology Median

Median of 608 stocks
MetricMBX.TOBiotechnology medianvs median
P/S ratio2.8513.300.2x the median
Profit margin−31.72%−38.31%6.6 pts above

Medians across 608 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Analysis

Data-derived

Company Overview

Microbix Biosystems Inc. (MBX.TO) carries a market capitalisation of CA$43.83M. The company sits in the Healthcare sector, in the Biotechnology industry.

The most recent close on file for MBX.TO is CA$0.32, dated October 21, 2026. The close was unchanged from the previous session. Over the past 52 weeks the price has ranged from CA$0.21 to CA$0.33. The latest close sits 52.38% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to CA$18.59M. That is −26.81% against the prior fiscal year, when revenue was CA$25.39M. The same year closed with a net loss of CA$2.25M. Profit margin runs at −31.72%. That is 6.6 percentage points above the Biotechnology median of −38.31%. Trailing earnings per share are −0.04.

Across the 4 fiscal years on file, revenue moves from CA$19.08M in 2022 to CA$18.59M in 2025. Of those 4 years, 2 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. The forward P/E on file is 16. The price-to-sales ratio is 2.85. On price-to-sales that is 0.2 times the Biotechnology median of 13.3. 608 Biotechnology companies report these metrics, and the medians quoted come from that group.

The reported beta is 0.54. Daily returns over the trailing 10 years annualize to a volatility of 61.28%. The trailing one-year total return is +28.00%. Across 10 years the annualized return works out at +2.50%.

Growth & Income

The record shows no dividend for MBX.TO.

So far in 2026 the total return is +39.13%. Across the complete calendar years on file, 2021 returned +93.02% and 2022 returned −50.60%. Of the 9 complete calendar years on file, 5 finished higher.

Peer Comparison

Microbix Biosystems Inc. (MBX.TO) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Microbix Biosystems Inc. MBX.TO CA$43.83M —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

Market caps are shown in each company's own trading currency, without conversion, and the peers are listed in order of these unconverted figures.

The Biotechnology industry average P/E ratio is 16.6x. Microbix Biosystems Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Microbix Biosystems Inc.

Microbix Biosystems Inc., a life science company, develops and commercializes proprietary biological and technological solutions for human health and wellbeing in North America, Europe, and internationally. The company manufactures a wide range of critical biological materials and medical devices for the global diagnostics industry, notably test ingredients (Antigen business) used in immunoassays, quality assessment, and diagnostic-test products, such as test-controls under the QAPs brand; viral transport medium for enabling the collection of patient samples to test for pathogens including virus causing the COVID-19 disease under the DxTM brand; Kinlytic, a biologic thrombolytic drug used to treat blood clots; and antigen products. It also provides customer vial filling services. Microbix Biosystems Inc. was founded in 1988 and is headquartered in Mississauga, Canada.

Visit website →